Key result
Combination therapy with interferon beta-1a and doxycycline significantly reduced contrast-enhancing lesion numbers and Expanded Disability Status Scale values (P < .001 for both).
Why the study?
Does combination therapy with interferon beta-1a and doxycycline improve gadolinium-enhancing lesion number change in patients with RRMS having breakthrough disease activity?
Does combination therapy with interferon beta-1a and doxycycline improve gadolinium-enhancing lesion number change in patients with RRMS having breakthrough disease activity?
p-value: p=<.001
Combination therapy with interferon beta-1a and doxycycline may reduce contrast-enhancing lesions and improve disability scores in patients with RRMS experiencing breakthrough disease activity.
No takes yet. Share an insight, caveat, or question.
May support adjunctive doxycycline in breakthrough RRMS; leaves open efficacy pending randomized trials.
Minagar et al. (2007) studied Relapsing-remitting multiple sclerosis (RRMS) (n=15). Combination therapy with intramuscular interferon beta-1a and oral doxycycline was evaluated on Gadolinium-enhancing lesion number change (p=<.001). Combination therapy with interferon beta-1a and doxycycline significantly reduced contrast-enhancing lesion numbers and Expanded Disability Status Scale values (P < .001 for both).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: